The financials
Avanos Medical, Inc. by the numbers
Avanos Medical, Inc. (AVNS) reported revenue of $182M in Q1 2026 (quarter ended Mar 31, 2026), up 8.8% from the same quarter a year earlier. That came with a gross margin of 52% and net income of $5.1M (2.8% of revenue). For the full year FY2025, revenue was $701M (+1.9% year on year) and net income −$73M. Its largest product in Q1 2026 was Enteral Feeding at $85M, 46% of the disclosed total, well ahead of Neonate Solutions at 22%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $182M | $168M | +8.8% |
| Gross profit | $94M | $90M | +4.9% |
| Operating income | $8.9M | $10M | −14% |
| Net income | $5.1M | $6.6M | −23% |
| Diluted EPS | $0.11 | $0.14 | −21% |
| Product | Revenue | Share |
|---|---|---|
| Enteral Feeding | $85M | 46% |
| Neonate Solutions | $39M | 22% |
| Radiofrequency Ablation | $35M | 19% |
| Surgical Pain And Recovery | $22M | 12% |
| Corporate Other | $1.9M | 1.0% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Mar 2026Total $182.2M (+2.5%)
Neonate Solutions grew +48% year on yearCorporate Other -81% year on year
Segment Latestquarter on quarteryear on year
- Enteral Feeding$84.6M$84.6MQoQ +2.3%year on year +14%+2.3%+14%
- Neonate Solutions$39.4M$39.4MQoQ +26%year on year +48%+26%+48%
- Radiofrequency Ablation$34.5M$34.5MQoQ -0.29%year on year +8.8%-0.29%+8.8%
- Surgical Pain And Recovery$21.8M$21.8MQoQ -11%year on year -11%-11%-11%
- Corporate Other$1.9M$1.9MQoQ -60%year on year -81%-60%-81%
Medical Devices
The closest names by size in the same industry